Neurocrine Biosciences Inc

Latest Neurocrine Biosciences Inc News and Updates

  • uploads///brain _
    Company & Industry Overviews

    Why Neurocrine Biosciences Stock Rose 9.6% Yesterday

    On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.

    By Daniel Collins
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///oral CR
    Company & Industry Overviews

    Cara Therapeutics’ Collaboration Agreements

    Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]

    By Kenneth Smith
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application for its investigational drug Elagolix had been granted priority review by the FDA.

    By Margaret Patrick
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Geographic Market Expansion to Boost Spinraza Sales in 2017

    In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

    By Margaret Patrick
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Neurocrine Analysts reco
    Company & Industry Overviews

    Neurocrine Biosciences: Ingrezza, Collaborations, Ratings

    In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Uterine Fibroids Segment May Offer Opportunity for NBIX

    According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Valbenazine Studies Seem Promising

    In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids

    Together, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) aim to develop Elagolix as a minimally invasive yet effective therapy for uterine fibroids

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain

    AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Become a Leading Uterine Fibroids Drug

    In addition to endometriosis, AbbVie’s (ABBV) and Neurocrine Biosciences’s (NBIX) Elagolix is also being investigated as a therapy for uterine fibroids.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?

    If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.